首页> 外文期刊>BMC Medical Research Methodology >Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
【24h】

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions

机译:行业支持的荟萃分析与无利润或无支持的荟萃分析的比较:方法学质量和结论的差异

获取原文
           

摘要

Background Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support. Methods We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses according to the type of support in 3 categories: industry-supported, non-profit support or no support, and undeclared support. Results We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11 undeclared support. On a 0–7 scale, the median quality score was 6 for meta-analyses with non-profit or no support and 2.5 for the industry-supported meta-analyses (P In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied that they had not received industry funding were added to those with non-profit or no support, and 3 who did not reply were added to those with industry support. This analysis did not change the results much. Conclusion Transparency is essential for readers to make their own judgment about medical interventions guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than meta-analyses with non-profit support or no support.
机译:背景研究表明,行业支持的药物荟萃分析缺乏科学严谨性,并且结论有误。但是,这些研究仅限于某些医学专业。我们将所有行业支持的药物比较的荟萃分析与没有行业支持的荟萃分析进行了比较。方法我们在PubMed中搜索所有比较了2004年发表的不同药物或不同类别药物的荟萃分析。两位作者评估了荟萃分析并独立提取了数据。我们使用经过验证的量表来评估方法学质量,并使用二元量表来评估结论。我们根据支持类型将荟萃分析分为三类:行业支持,非营利支持或无支持以及未声明的支持。结果我们纳入了39项荟萃分析。有10个获得了行业支持,有18个非营利或没有支持,还有11个未声明支持。在0–7量表上,有非盈利或无支持的荟萃分析的中位质量得分为6,而行业支持的荟萃分析的中位质量得分为2.5(P在敏感性分析中,我们联系了荟萃分析的作者在没有声明支持的情况下,有八位回答他们没有得到行业资助的人被添加到了非营利或没有支持的人中,有三位没有回答的人被添加到了有行业支持的人中,这一分析并没有太大改变。透明对于读者在荟萃分析结果指导下对医疗干预措施做出自己的判断至关重要,我们发现,行业支持的荟萃分析的透明度不如带有非营利支持或不支持的荟萃分析透明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号